… bile, and as such patients with impaired hepatic function were … dosing in patients with cancer
with hepatic dysfunction was … for pharmacologic analysis.) during the conduct of the study. …

… of liver function in patients with different cancers. The severity of … the organ dysfunction,
pharmacokinetics and pharmacology … such as the NCI Organ Dysfunction Working Group (NCI-…

… allowed many mCRC patients to be … study, the rate conversion surgery to patients with
oxaliplatin-based chemotherapy was about 40%. Even in patients with impaired renal function (Ccr…

… oxaliplatin (CAPOX) is a standard treatment for resected colon cancer; however, in patients
with moderate renal impairment, … National Cancer Institute Organ Dysfunction Working Group …

… oxaliplatin is limited for patients with impaired renal function. … Dose-escalating and
pharmacological study of Oxaliplatin in adult cancer patients with impaired renal function: a National …

… In a post hoc analysis of a study using the CG formula (milliliters per minute) to dose stratify
patients with impaired kidney function being administered oxaliplatin to develop dosing …

… Historically, patients with impaired kidney function have been excluded from phase 1 studies
of anticancer drugs because of a perceived increased risk for major dose-limiting toxicity. A …

… BM, Ivy P National Cancer Institute Organ Dysfunction Working Group. Dose-escalating and
pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a …

… TMA is associated with poor outcomes and does not have an established treatment. Mild …
to oxaliplatin, as well as TMA.71, 72, 73, 74 Another notable complication of oxaliplatin is …

… The second-generation carboplatin and nedaplatin as well as third-generation oxaliplatin
were developed as derivatives of cisplatin and all have reduced side effects, such as …